Carregant...
An exploratory analysis of the efficacy of ocrelizumab in patients with multiple sclerosis with increased disability
BACKGROUND: Ocrelizumab, an anti-CD20 humanized monoclonal antibody, reduced disease progression in pivotal trials of patients with relapsing (OPERA I, OPERA II) and primary progressive (ORATORIO) multiple sclerosis (MS). These effects may be particularly important among patients with increased disa...
Guardat en:
| Publicat a: | Mult Scler J Exp Transl Clin |
|---|---|
| Autors principals: | , , , , , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
SAGE Publications
2020
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7079307/ https://ncbi.nlm.nih.gov/pubmed/32206332 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1177/2055217320911939 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|